Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 1Phase 3 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 298Carcinoma, Non-Small-Cell Lung 226Neoplasms 155Prostatic Neoplasms 154Multiple Myeloma 116Neoplasm Metastasis 83Colorectal Neoplasms 80Leukemia, Myeloid, Acute 74Lung Neoplasms 71Parkinson Disease 4, Autosomal Dominant Lewy Body 68Melanoma 67Leukemia, Lymphocytic, Chronic, B-Cell 63Lymphoma, Follicular 62Lymphoma, Non-Hodgkin 61Papillomavirus Infections 59Leukemia 59Pain 52Lymphoma 52Uterine Cervical Neoplasms 50Precursor Cell Lymphoblastic Leukemia-Lymphoma 49Ovarian Neoplasms 47Carcinoma, Hepatocellular 46Keratosis, Actinic 44Carcinoma, Renal Cell 44Recurrence 43Head and Neck Neoplasms 43Stomach Neoplasms 38Lymphoma, Large B-Cell, Diffuse 34Urinary Bladder Neoplasms 33Squamous Cell Carcinoma of Head and Neck 32

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Has results × Hypersensitivity × Clear all
NCT06240741 2026-02-03

A Prospective, Open-label Study of [68Ga]Ga-DOTA-TATE in Patients With Neuroendocrine Neoplasms (NENs) and Healthy Volunteers in Japan

Novartis

Phase 3 Completed
71 enrolled 37 charts

Hypersensitivity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡